JP2020537534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537534A5 JP2020537534A5 JP2020531804A JP2020531804A JP2020537534A5 JP 2020537534 A5 JP2020537534 A5 JP 2020537534A5 JP 2020531804 A JP2020531804 A JP 2020531804A JP 2020531804 A JP2020531804 A JP 2020531804A JP 2020537534 A5 JP2020537534 A5 JP 2020537534A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- echo25
- cancer
- seq
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000190163 Echovirus E25 Species 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 239000002299 complementary DNA Substances 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 241000710124 Human rhinovirus A2 Species 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091023045 Untranslated Region Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 108091023685 miR-133 stem-loop Proteins 0.000 claims 2
- 108091063796 miR-206 stem-loop Proteins 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 241000702244 Orthoreovirus Species 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- -1 anthracyclines (e.g. Chemical compound 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011188 breast medullary carcinoma Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710734483.1A CN109419818B (zh) | 2017-08-24 | 2017-08-24 | 一种用于治疗肿瘤的埃可病毒 |
| CN201710734483.1 | 2017-08-24 | ||
| PCT/CN2018/100708 WO2019037642A1 (zh) | 2017-08-24 | 2018-08-15 | 一种用于治疗肿瘤的埃可病毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537534A JP2020537534A (ja) | 2020-12-24 |
| JP2020537534A5 true JP2020537534A5 (https=) | 2021-08-26 |
| JP7373168B2 JP7373168B2 (ja) | 2023-11-02 |
Family
ID=65439346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531804A Active JP7373168B2 (ja) | 2017-08-24 | 2018-08-15 | 腫瘍を治療するためのエコーウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11707496B2 (https=) |
| EP (1) | EP3674398A4 (https=) |
| JP (1) | JP7373168B2 (https=) |
| KR (1) | KR102818964B1 (https=) |
| CN (1) | CN109419818B (https=) |
| AU (1) | AU2018320550B2 (https=) |
| CA (1) | CA3073770A1 (https=) |
| WO (1) | WO2019037642A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765048B1 (en) * | 2018-03-12 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Using infectious nucleic acid to treat cancer |
| KR102789613B1 (ko) * | 2019-11-26 | 2025-04-01 | 난트퀘스트, 인크. | 일차 nk car 구축물 및 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002953436A0 (en) * | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| WO2006074526A1 (en) * | 2005-01-17 | 2006-07-20 | Viralytics Limited | Method and composition for treatment of neoplasms |
| EP2125032A4 (en) | 2007-02-20 | 2011-02-23 | Mayo Foundation | CANCER TREATMENT WITH VIRAL NUCLEIC ACID |
| RU2436873C2 (ru) | 2010-01-20 | 2011-12-20 | Федеральное государственное образовательное учреждение высшего профессионального образования "РОССИЙСКИЙ ГОСУДАРСТВЕННЫЙ АГРАРНЫЙ ЗАОЧНЫЙ УНИВЕРСИТЕТ" | Устройство для нанесения покрытий |
| KR101942237B1 (ko) | 2011-01-04 | 2019-01-25 | 신라젠(주) | 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산 |
| RU2496873C1 (ru) * | 2012-06-04 | 2013-10-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (НГУ) | ШТАММ ЭНТЕРОВИРУСА КОКСАКИ В6, СЕЛЕКТИВНО ИНФИЦИРУЮЩИЙ И ЛИЗИРУЮЩИЙ ОПУХОЛЕВЫЕ КЛЕТКИ ЧЕЛОВЕКА in vitro |
| JP6396891B2 (ja) | 2013-04-17 | 2018-09-26 | 新日本製薬株式会社 | 遺伝子改変コクサッキーウイルス |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| CN107669707A (zh) | 2017-11-16 | 2018-02-09 | 邹罡 | 埃可病毒作为溶瘤病毒在抗肿瘤中的应用 |
-
2017
- 2017-08-24 CN CN201710734483.1A patent/CN109419818B/zh active Active
-
2018
- 2018-08-15 EP EP18849336.5A patent/EP3674398A4/en active Pending
- 2018-08-15 US US16/641,117 patent/US11707496B2/en active Active
- 2018-08-15 JP JP2020531804A patent/JP7373168B2/ja active Active
- 2018-08-15 KR KR1020207008441A patent/KR102818964B1/ko active Active
- 2018-08-15 WO PCT/CN2018/100708 patent/WO2019037642A1/zh not_active Ceased
- 2018-08-15 AU AU2018320550A patent/AU2018320550B2/en active Active
- 2018-08-15 CA CA3073770A patent/CA3073770A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6419706B2 (ja) | ミニプロモーターカセットを含むレトロウイルスベクター | |
| Zhang et al. | Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery | |
| JP2020528890A5 (https=) | ||
| JP2015530359A5 (https=) | ||
| JP6961788B2 (ja) | プログラム可能な腫瘍溶解性ウイルスワクチン系及びその適用 | |
| JP2021522190A5 (https=) | ||
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| TWI545196B (zh) | Ｒｅｉｃ表現腺病毒載體 | |
| CN115232217B (zh) | 一种SynNotch结构及其应用 | |
| CN110387353B (zh) | 一种用于治疗肿瘤的柯萨奇b组病毒 | |
| JP2020537534A5 (https=) | ||
| Younis et al. | Understanding gene involvement in hepatocellular carcinoma: Implications for gene therapy and personalized medicine | |
| Cao et al. | MDA7 combined with targeted attenuated Salmonella vector SL7207/pBud-VP3 inhibited growth of gastric cancer cells | |
| US20240417694A1 (en) | Modulating venuleness of endothelial cells | |
| Esmaeilzadeh et al. | Chimeric antigen receptor (CAR) T Cell immunotherapy for solid tumors | |
| WO2016187908A1 (zh) | 重组溶瘤腺病毒及其应用 | |
| JPWO2019201192A5 (https=) | ||
| CN109419818B (zh) | 一种用于治疗肿瘤的埃可病毒 | |
| Wang et al. | Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo | |
| CN116670172A (zh) | 表达免疫检查点抑制剂的癌症特异性反式剪接核酶及其用途 | |
| JP7618299B2 (ja) | 免疫チェックポイント阻害剤を発現するがん特異的トランス－スプライシングリボザイム及びこの用途｛ｔｕｍｏｒ－ｔａｒｇｅｔｉｎｇ ｔｒａｎｓ－ｓｐｌｉｃｉｎｇ ｒｉｂｏｚｙｍｅ ｅｘｐｒｅｓｓｉｎｇ ｉｍｍｕｎｅ ｃｈｅｃｋｐｏｉｎｔ ｉｎｈｉｂｉｔｏｒ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ | |
| Takigawa et al. | Antitumor effect induced by dendritic cell (DC)-based immunotherapy against peritoneal dissemination of the hamster pancreatic cancer | |
| CN117737072A (zh) | 一种预防或治疗肿瘤的mRNA疫苗及其应用 | |
| Seth et al. | Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer | |
| CN101168742A (zh) | 一种溶癌病毒及其制备方法 |